[A new probe for congenital nasolacrimal duct obstruction].
To investigate the therapeutic effect of a new probe for congenital nasolacrimal duct obstruction. The probe was designed and manufactured by ourselves. We observed 158 cases (172 eyes) with congenital nasolacrimal duct obstruction and treated them with the probe 1-3 times. The mean period of postoperative follow-up was 17.8 (range 12-24 months) months. The success rate was 98.2%. Common complications included a slight blood-stained nasal discharge. Our newly designed and manufactured probe provides a new probe for congenital nasolacrimal duct obstruction. The probe is a safe, simple and effective treatment method for congenital nasolacrimal duct obstruction.